The estimated Net Worth of Jay M Phd Short is at least 15.3 百万$ dollars as of 20 December 2023. Dr Short owns over 50,000 units of BioAtla stock worth over 2,576,317$ and over the last 9 years he sold BCAB stock worth over 11,705,515$. In addition, he makes 1,057,577$ as Co-Founder、 CEO & Chairman at BioAtla.
Dr has made over 10 trades of the BioAtla stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of BCAB stock worth 107,000$ on 20 December 2023.
The largest trade he's ever made was selling 146,137 units of BioAtla stock on 14 June 2021 worth over 5,854,248$. On average, Dr trades about 14,089 units every 24 days since 2015. As of 20 December 2023 he still owns at least 1,439,283 units of BioAtla stock.
You can see the complete history of Dr Short stock trades at the bottom of the page.
Dr. Jay M. Short is the Co-Founder, CEO & Chairman at BioAtla.
As the Co-Founder、 CEO & Chairman of BioAtla, the total compensation of Dr Short at BioAtla is 1,057,577$. There are no executives at BioAtla getting paid more.
Dr Short is 63, he's been the Co-Founder、 CEO & Chairman of BioAtla since . There are 1 older and 5 younger executives at BioAtla. The oldest executive at BioAtla, Inc. is Richard A. Waldron, 67, who is the Chief Financial Officer.
Jay's mailing address filed with the SEC is C/O BIOATLA, INC. 11085 TORREYANA ROAD, , SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at BioAtla have traded over 51,913,006$ worth of BioAtla stock and bought 2,491,625 units worth 40,365,176$ . The most active insiders traders include Guy Levy、Asset Management, Lp Chen B...、Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of 157,753$. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth 9,320$.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BioAtla executives and other stock owners filed with the SEC include: